Qureight provides two integrated products for pharmaceutical clinical trials: Workflow, which speeds imaging decision turnaround from about two weeks to 48 hours, and AI Lung, which constructs detailed models of airways and blood vessels from chest scans. The company has built a general-purpose foundation model of the chest that enables development of disease-specific deep learning models in one to two months. Qureight is running global clinical trials with partners including AstraZeneca, Bristol Myers Squibb, and several biotech firms. Founded in 2018, the company combines clinical leadership—co-founder and CEO Dr Muhunthan Thillai continues clinical work—with a senior technical team recruited from industry and academia. Financially, Qureight has raised a £1.5 million seed in 2022 and the recent $20 million Series B to support lab build-out, therapeutic-area expansion, and headcount growth.

Total raised

$31M

Funding rounds

4

Latest round

Series B

Latest activity

Jul 2026